The antagonist protocol using gonadotropin‐releasing hormone (GnRH) antagonists has attracted attention for its ability to minimize the risk of ovarian hyperstimulation syndrome (OHSS), as a potentially severe complication.4, 5. Here, GNRH1 is linked to ovarian hyperstimulation syndrome.